Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo

被引:117
作者
Erdmann, AA
Gao, ZG
Jung, U
Foley, J
Borenstein, T
Jacobson, KA
Fowler, DH
机构
[1] NCI, NIH, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA
[2] NIDDK, Bioorgan Chem Lab, NIH, Mol Recognit Sect, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood-2004-04-1407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the direct effect of adenosine on cytokine-polarized effector T cells, murine type 1 helper T cells (Th1) and type 1 cytotoxic T lymphocytes (Tc1) and Th2/Tc2 cells were generated using an antigen-presenting cell (APC)-free method. Tc1 and Tc2 cells had similar adenosine signaling, as measured by intracellular cyclic AMP (cAMP) increase upon adenosine A(2A) receptor agonism by CGS21680 (CGS). CGS greatly reduced Tc1 and Tc2 cell interleukin 2 (IL-2) and tumor necrosis factor alpha (TNF-alpha) secretion, with nominal effect on interferon gamma (IFN-gamma) secretion. Tc2 cell IL-4 and IL-5 secretion was not reduced by CGS, and IL-10 secretion was moderately reduced. Agonist-mediated inhibition of IL-2 and TNF-alpha secretion occurred via A(2A) receptors, with no involvement of A(1), A(2B), or A(3) receptors. Adenosine agonist concentrations that abrogated cytokine secretion did not inhibit Tc1 or Tc2 cell cytolytic function. Adenosine modulated effector T cells in vivo, as CGS administration reduced CD4(+)Th1 and CD8(+)Tc1 cell expansion to alloantigen and, in a separate model, reduced antigen-specific CD4(+)Th1 cell numbers. Remarkably, agonist-mediated T-cell inhibition was abrogated by in vivo IL-2 therapy. Adenosine receptor activation therefore preferentially inhibits type I cytokine secretion, most notably IL-2. Modulation of adenosine receptors may thus represent a suitable target primarily for inflammatory conditions mediated by Th1 and Tc1 cells. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:4707 / 4714
页数:8
相关论文
共 33 条
[1]   Study of A2A adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A2A receptor-unrelated lymphotoxicity [J].
Apasov, SG ;
Chen, JF ;
Smith, PT ;
Schwarzschild, MA ;
Fink, JS ;
Sitkovsky, MV .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (01) :43-50
[2]   An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation [J].
Asseman, C ;
Mauze, S ;
Leach, MW ;
Coffman, RL ;
Powrie, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) :995-1003
[3]   Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets [J].
Carter, LL ;
Dutton, RW .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) :336-342
[4]   An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response [J].
Chiaramonte, MG ;
Donaldson, DD ;
Cheever, AW ;
Wynn, TA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (06) :777-785
[5]  
FOWLER DH, 1994, J IMMUNOL, V152, P1004
[6]  
Fredholm BB, 2001, PHARMACOL REV, V53, P527
[7]  
Hasko G, 1996, J IMMUNOL, V157, P4634
[8]  
HIDE I, 1992, MOL PHARMACOL, V41, P352
[9]   Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion [J].
Huang, S ;
Apasov, S ;
Koshiba, M ;
Sitkovsky, M .
BLOOD, 1997, 90 (04) :1600-1610
[10]  
JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888